印度尼西亚研究人员对伊维菌素进行元分析：发现针对 COVID-19 的令人信服的功效
在英国的研究注册中心 PROSPERO 中注册，并附有他们的结果
发表在同行评审医学期刊“医学病毒学评论”上，来自印度尼西亚 Pelita Harapan 大学的团队进行了荟萃分析
伊维菌素给药是否能有效改善 COVID-19 患者的预后这一重要问题？
遵守所谓的“PICO”框架，
意味着该研究遵循以下
P：人口—Covid-19 患者；
I：干预—伊维菌素药物；
C：比较或对照
一组未接受伊维菌素，仅接受标准护理疗法或任何其他药物作为对照/安慰剂的患者；
O：结果
严重的 Covid-19，死亡率，
阴性 RT-PCR 检测结果率，
RT-PCR 检测结果呈阴性的时间、症状缓解率、
症状缓解的时间，
出院时间，
包括随机临床试验文章，条件是全文发表。
Undertaking an extensive search in PubMed,
Europe PMC,
ClinicalTrials.gov,
the team assessed the quality of underlying studies using Jadad scale assessment, a tool for clinical trial studies.
Employing Review Manager 5.4 software for their statistical analysis,
the researchers reviewed 19 studies with 2,768 COVID-19 patients in the study.
They found that ivermectin was associated with a reduction in the severity of COVID-19,
reduction of mortality,
higher negative RT-PCR test result rate, shorter time to negative RT-PCR test results,
higher rate of reducing COVID symptoms,
shorter hospitalization duration as measured by time to discharge.
Yet another comprehensive meta-analysis
suggests ivermectin could offer beneficial effects when treating COVID-19.
Of course, the scholars recommend more clinical trials, as have all other researchers delving into the matter.
The Indonesia-based team
sought to provide some more clarity in the discussion about the efficacy of ivermectin,
clarifying whether they could find the evidence for ivermectin and its contribution to positive outcomes.